Stifel on Apogee Therapeutics Inc (APGE): 'We think a PK profile supporting Q6W/Q8W dosing in Ph1 could see shares up 30-50%'
Tweet Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $95.00 price target on Apogee Therapeutics Inc (NASDAQ: APGE).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
